Table of Contents

Pharmaceuticals regulation across OECD Countries
Maximising value for money to improve health system performance

The multiple goals of regulation

INTERNATIONAL PERSPECTIVES

COMMON CHALLENGES

Canada in the global perspective

Total expenditure on pharmaceutical goods as a share of GDP

Link between total expenditure on pharmaceutical goods per capita and GDP per capita at current exchange rates

Link between total expenditure on pharmaceutical goods per capita and GDP at purchasing power parities

Total expenditure on pharmaceutical goods as a percentage of total expenditure on health

ECONOMIC CONTEXT

THE REGULATION OF DEMAND

RECENT TRENDS

Public pharmaceutical expenditure within total pharmaceutical expenditure (in %)

SUPPLY SIDE

A SECOND BEST SOLUTION ?

FIXING PRICES ?

ASSESSING THE IMPACT

Relative price trends for pharmaceuticals

Ttrends in the measure growth rate of total and of public expenditures on pharmaceutical goods, 1980-1996

PROFIT CONTROLS RATE OF RETURN

THE EMPIRICAL PERSPECTIVE

An example: recent OECD study on cardiovascular disease and stroke:

Trends in unit expenditure by therapeutic subclass

PUZZLING RESULTS

EXPENDITURE TRENDS

REFERENCE PRICING

REFERENCE PRICING

DIRECT EXPENDITURE CONTROL

IMPROVING HEALTH SYSTEM PERFORMANCE

Involving physicians: monitoring prescription

Assessing the value of pharmaceuticals

THE BROADER POLICY IMPLICATIONS

THE IMPOSSIBILITY TRIANGLE

POLICY IMPLICATIONS

CONCLUSION

Presentation Author

Stephane Jacobzone, OECD Health Project
( http://www.oecd.org )

PMPRB Email

pmprb@pmprb-cepmb.gc.ca

PMPRB Symposium 2002, List of Presentations

http://www.pmprb.com/symposium2002/present-e.html